Li-ion Motors Corp. (OTC BB: LMCO.OB)

Recently, LMCO announce that they have advanced in the Progressive Insurance Automotive X-Prize. After careful consideration of their submitted materials, the Technical Team has accepted their 3rd Technical Deliverable. Their scorecard from TD3 was attached stating … well done!”

Their next stop, was Michigan International Speedway for the first on track event to dial in the vehicles and test data transmission equipment.

Also, their was a scorecard which reports pass or fail on four essential performance areas. To my surprise, LMCO passed all four tests. One of the tests was an accumulating mileage of 100 miles showing the car has been driven and continues to drive up to go green expectations.

LMCO’s entry into the X-Prize is an Electric vehicle powered by Lithium-ion batteries. I am not talking about a hybrid. I am talking about a true electric car.

Furthermore, LMCO announced Their participation at the 40th year anniversary Earth Day celebration event by “PINKS All Out” at zMAX Dragway, Charlotte Motor Speedway.

Remember, the name of the game is speed.

Who would of thought, that the loud sounds of machines could go green?

I guess, in my opinion it sound clean to go green and make some green?

To view LMCO interactive chart Click Here

“Really it’s just an evolution. Why would we go backwards? If there’s ways to make it more efficient, faster and cleaner, why wouldn’t we?”

“Any performance shop that isn’t keeping their eye on green right now… to get cars to go faster and cleaner is making a mistake” says Rich Christensen, host of the race TV reality show “PINKS All Out” on cable TV’s “SPEED”

I remember when I was younger I said, “that the problem with radio controlled cars was that they were too slow and didn’t make it across the street”.

Growing up, others would say that the problem with electric cars would be that they are too slow .

Not anymore!

To view Experts views on Li-ion Motors Electric Car on You Tube Click Here

“I believe racing can go green.” Ron Cerven of LMCO of Mooresville (that’s Li-ion short litihum ion) showed us their wave car than can go 90 miles an hour, and they built a battery powered race car that tops out at 160.

To view Ron Cerven of LMCO of Mooresville on You Tube Click Here

In my opinion that sounds great!

How are we to control oil, with matters of the gulf of mexico oil spill arising?

White House spokesman Robert Gibbs recently reported that despite last week’s oil spill the president “still continues to believe the great majority of that can be done safely, securely and without any harm to the environment.”

Recently, President Barack Obama visited an electric car factory in California and urged workers to help the country lead.

To view President Barack Obama at a electric car factory on You Tube Click Here

So let me ask you, does going green sound like a good thing?

About Li-ion Motors Corp.

Li-ion Motors Corp., a development stage technology company, engages in the design and engineering of emission-free automotive propulsion systems utilizing the lithium battery technology in the United States, Europe, and the Middle East. The company sells electric, lithium powered, and converted vehicles. Its product line includes cars, motor cycles, mopeds, and power sport vehicles.

Visit Li-ion Motors Corp. (LMCO.OB) for more information at http://www.li-ionmotors.com

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand dollars from a third party (Wazalmin Capital Corp.) for 1 day of advertisement services for Li-ion Motors Corp. (OTCBB: LMCO) .

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

***************************ADVERTISEMENTS**************************

LMCOpennyotcstock0430

HOUSTON–(CRWENEWSWIRE)–Please replace the release dated April 28, 2010 with the following corrected version due to multiple revisions in the fifth paragraph.

Corrected release reads:

THE INTERNATIONAL CONGRESS OF ALZHEIMER’S DISEASE ACCEPTS FOUR SCIENTIFIC PRESENTATIONS BY POWER3

Power3 Presents NuroPro® to ICAD for the 2nd Year in a Row

Power3 Medical Products, Inc. (OTCBB: PWRM – News) announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer’s Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro® AD biomarkers and blood test for Alzheimer’s disease. The four studies to be presented involve a total of 154 Alzheimer’s disease patients and 91 Parkinson’s disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

The NuroPro® AD biomarkers and blood test are intended to help clinicians distinguish patients with Alzheimer’s disease from “normal” individuals, i.e., patients with similar, non-Alzheimer’s neurological disorders. They are also intended to solve the critical challenge facing physicians, clinicians, patients and drug developers, who all need tests for early stage accurate and specific diagnosis of this debilitating disease, as well as more guidance for drug therapy, patient selection for drug clinical trials, and better tools to monitor drug treatment response.

The abstracts report the use of combined results from ongoing clinical validation trials of NuroPro® AD. The trials are being conducted by the Power3 scientific team, led by scientific advisory board member Lourdes R. Bosquez, MD and Chief Scientific Officer, Ira L. Goldknopf, Ph.D. in collaboration with Marwan Sabbagh, MD, director of the Banner Sun Health Research Institute. The team is also utilizing previous studies Power3 conducted with Stanley H. Appel, MD during his tenure as Chairman of Neurology at the Baylor College of Medicine and, currently, as Co-Director of the Methodist Neurological Research Institute. Dr. Appel continues to be chairman of the scientific advisory board of Power3.

“These 4 posters represent the culmination of 7 years of hard scientific effort which we have been blessed to pursue with our distinguished collaborators,” said Dr. Goldknopf. “There will be some surprises for our colleagues at ICAD that we are particularly excited about because they have the potential to guide us towards improvements in treatment for this awful illness.” Dr. Goldknopf will present two of the posters at ICAD, one on NuroPro® AD biomarkers for Alzheimer’s specific diagnosis and the other on NuroPro® AD diagnostic clinical validation trials. Dr. Sabbagh will present a third poster on prospective clinical validation of the use of protein biomarkers from newly drawn patient sera for diagnosis of Alzheimer’s disease, and Dr. Bosquez will present a fourth poster on NuroPro® AD protein biomarkers and drug response.

“We are proud that Dr. Goldknopf will be joined this year by two members of our scientific advisory board, Dr. Sabbagh and Dr. Bosquez, in presenting to ICAD 2010,” said Helen R. Park, MS, Chief Executive Officer of Power3. “For us to present four posters at the same time at such a prestigious forum speaks to the depth of our science and our commitment to improving the outcomes for patients with Alzheimer’s disease. This work, in conjunction with the recent filing of a patent application that is subject to assignment by its inventors to StemTroniX upon the consummation of the acquisition of StemTroniX by Power3, bodes well for Power3’s upcoming acquisition of StemTroniX.”

Power3 Medical Products

Power3 Medical Products, Inc. is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, and to identify protein biomarkers and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro®) and breast cancer (BC-SeraPro™). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.

For more information, please visit http://www.power3medical.com

StemTroniX

StemTroniX, Inc. is a stem cell biotechnology holding and acquisition company that is committed to improving the lives of individuals by using autologous adult stem cell technology to repair tissue damage in patients. Autologous adult stem cell therapy is the process of using an individual’s own stem cells for the purpose of repairing and regenerating damaged tissue. StemTroniX also provides a patented system to augment this process in a non-invasive method for in-body monitoring of the stem cells at the site of injury as they are being introduced into the patients.

For more information, please visit http://www.stemtronix.com

Safe Harbor Provision

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the company’s future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2009 and its other filings and submissions with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company assumes no obligation to update or revise any of the information contained in this press release.

Contact:

Crown Equity Holdings, Inc.

Ken Bosket, 877-854-6797 or 702-448-1543

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and disseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

***************************ADVERTISEMENTS**************************

PWRMpennyotcstock0430

View Systems, Inc. (OTC BB: VSYM)

Recently, VSYM announced that the company has retained Laidlaw & Company to complete a strategic investment banking deal.

Laidlaw & Company is a full service investment bank and securities brokerage firm with offices in New York, London, Miami and select additional locations. Its brokerage arm provides wealth management advice for domestic and international high-net-worth and institutional clients. Its investment banking arm provides capital raising, M&A, restructuring and other financial advisory services for public and private small cap and middle market clients across a broad cross-section of industry sectors. Laidlaw is authorized by the FSA in the United Kingdom, and is regulated by FINRA in the United States. (Source: www.laidlawltd.com).

VSYM CEO, Gunther Than, states, “The engagement of Laidlaw & Company will be an asset to View. Laidlaw will assist VSYM in business development, review for potential M&A candidates and enhance shareholder value. We are organizing the details of the plan and putting it into action.”

Also, VSYM announced that the company’s leading authorized international dealer and business partner, Belcom, is in negotiations with Dr. Naseeb Qirbi to launch a marketing initiative that would call for the delivery of approximately 100 plus VSYM ViewScan systems by the 2010 year end.

The government of Yemen is seeking to secure the premises of each of their embassies around the world. Upon finalization of the agreement, Belcom will place an order to View to fulfill the requisition for 100 or more VSYM ViewScan units that would then be placed in each of the Yemenite embassies, and in some high-traffic office buildings.

Gautham Belthur, General Manager of Belcom, states, “The government of Yemen is not only interested in the VSYM ViewScan, but they are also interested in VSYM’s other products, including but not limited to the MMV and Mini.”

Furthermore, let’s not forget that VSYM has been selected yet again for the Best of Baltimore Award in the Security Control Equipment and Systems category by the U.S. Commerce Association.

About View Systems, Inc.

View Systems, Inc. manufactures and installs weapons detection identification systems, video management platforms and tele-data communication networks targeted towards correctional facilities, schools, courthouses, government agencies, event and sports venues, and commercial businesses.

Visit View Systems, Inc. (VSYM.OB) for more information at www.viewsystems.com

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) was previously compensated five hundred thousand shares from a third party for 60 days (which has expired) of advertisement services for View Systems Inc. (VSYM.OB) during the year of 2009.

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

***************************ADVERTISEMENTS**************************

VSYMpenntotcstock0430

Acme Packet, Inc.(NasdaqGS: APKT)

Recently, APKT announced record results for the first quarter ended March 31, 2010 and raised its business outlook for 2010.

APKT total revenue for the first quarter of 2010 was $51.1 million, compared to $31.0 million in the first quarter of 2009 and $41.3 million in the fourth quarter of 2009. Net income for the first quarter of 2010 was $8.3 million, or $0.13 per share on a diluted basis, compared to $2.8 million, or $0.05 per share on a diluted basis in the first quarter of 2009 and $9.1 million, or $0.14 per share on a diluted basis, in the fourth quarter of 2009. Net income on a non-GAAP basis for the first quarter of 2010 was $10.7 million, or $0.16 per share on a diluted basis, compared to $4.3 million, or $0.07 per share on a diluted basis, in the first quarter of last year, and $6.8 million, or $0.11 per share on a diluted basis, in the fourth quarter of 2009.

About Acme Packet, Inc.

Acme Packet, Inc. provides session border controllers (SBCs) that enable service providers, enterprises, and contact centers to deliver interactive communications and data services across Internet protocol (IP) network borders in the United States, Canada, and internationally. The SBCs are deployed at the borders between IP networks, such as between two service providers; between a service provider and its enterprise, residential, or mobile customers; and between enterprises IP network and their service providers network.

Visit Acme Packet, Inc. (APKT) for more information at http://www.acmepacket.com

Delivery Technology Solutions, Inc. (Other OTC: DTSL.PK)

DTSL, a leader in Delivery Management Solutions CEO Ryan Coblin recently appeared on The Princeton Research Investment Talk Radio Show with Host Mike King.

Mr. Coblin discussed the current state of affairs and future prospects of DTSL, as well as answered live listener questions.

“I am excited to have this opportunity to share some of our recent successes with the listeners,” stated CEO Ryan F. Coblin, “and to communicate any timely information to our shareholders of the opportunities that await us here at DTSL.”

Furthermore, DTSL provides comprehensive custom-developed catering/delivery solutions to industries throughout North America, including restaurants and retail.

“We want consumers to think of SUBWAY® Restaurants first for catering and delivery,” stated Mr. Ryan Coblin, CEO and Chairman of Delivery Technology Solutions, Inc., “One of the most recognized of all brands, SUBWAY® Restaurants will now be delivering catering options direct to the door of businesses, residences and other venues. In short, select SUBWAY® Restaurants are now going to be just a call, or click, away.” David Dickerson, Vice President of Operations, SUBWAY® Development Corporation of Washington, remarked, “SDC is very pleased to partner with UDS and excited about the opportunities this program brings for our franchise owners to target the corporate and residential catering markets.”

Yesterday, DTSL announced the extension of their agreement with Doctor’s Associates Inc. (DAI), the parent of SUBWAY® Restaurants. The agreement will continue through December 31, 2010, for the 888-SUB-TO-GO™ program pilot that has been operating in the Washington, DC Metro area since Fall 2009. The announcement was made by Ryan Coblin, Delivery Technology Solutions, Inc, Chairman/CEO.

“We are pleased and encouraged by the extension of our agreement with DAI for SUBWAY® Restaurants in the Washington area,” said Mr. Coblin, “and we view it as affirmation of the success we have had in implementing our proprietary technology and exclusive solutions in and around the nation’s capital.”

About Delivery Technology Solutions, Inc.

Delivery Technology Solutions, Inc., the leader in providing comprehensive custom-developed catering & delivery solutions to industries throughout North America, including restaurants, retail and others. The company’s solutions offer a seamless system that integrates Customer Relationship Management (CRM) and Call Center IT services through a proprietary technology backbone to offer convenience, consistent quality, flexibility, accountability and value for consumers and companies. 888-SUB-TO-GO™is the trademark of Universal Delivery Solutions, Inc.

Visit Delivery Technology Solutions, Inc. (DTSL.PK) for more information at http://www.deltechsol.com

***************************ADVERTISEMENTS**************************

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is expected to be paid ten thousand dollars from a third party (New Republic) for two days of advertisement services for Delivery Technology Solutions, Inc. (DTSL.PK).

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

DTSLpennyotcstock0430

Dendreon Corp. (NasdaqGM: DNDN)

DNDN today announced that management will present at the following investor conferences in May.

Late last thursday, DNDN announced that its prostate cancer therapy Provenge had finally been approved by the U.S. Food and Drug Administration.

About Dendreon Corp.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant prostate cancer; and (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to Trp Ion Channel, for multiple cancers.

Visit Dendreon Corp. (DNDN) for more information at http://www.dendreon.com

Power3 Medical Products, Inc. (OTC BB: PWRM.OB)

PWRM signed a definitive agreement to acquire all of the stock of StemTroniX Inc., a Texas corporation (”StemTroniX”). PWRM plans to effectuate the acquisition of StemTroniX by merging a wholly-owned subsidiary of the Company with and into StemTroniX. StemTroniX will remain as the surviving company in the merger and will become a wholly-owned subsidiary of PWRM. The acquisition of StemTroniX is expected to be completed April 2010.

Furthermore, April 27, 2010 StemTroniX, Inc., and PWRM announced that a plenary address entitled “The Genesis of Prototype Biomarkers for Identification and Use of Stem Cells for Therapeutics of Alzheimer’s Disease” will be delivered by Ira L. Goldknopf, PhD, Power3’s President and Chief Scientific Officer, to the European Molecular Histopathology Symposium on The Impact of Personalized Medicine, April 29, 2010, in Chantilly, France, organized by Ventana Medical Systems, a member of the Roche Group.

The focus of this presentation is on the progress Power3 and StemTroniX have made towards enhanced effectiveness of Alzheimer’s disease therapy by combining StemTroniX’s patented and patent pending adult stem cell regenerative medicine technologies with PWRM patent pending blood serum adult stem cell protein biomarkers and diagnostic technologies. StemTroniX’s technologies include a licensed patent and several patent disclosures for monitoring of stem cell therapy, technology to aid in the viability of adult stem cells, injection technology, and non-invasive imaging technology. These technologies complement Power3’s technologies for Alzheimer’s specific diagnosis, multiple forms of Alzheimer’s disease, response to Alzheimer’s drug therapy, predictive drug response, and discovery of more clinically relevant tissue, blood and adult stem cell biomarkers.

Recently, April 28, 2010 PWRM announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer’s Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro® AD biomarkers and blood test for Alzheimer’s disease. The four studies to be presented involve a total of 154 Alzheimer’s disease patients and 91 Parkinson’s disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

“These 4 posters represent the culmination of 7 years of hard scientific effort which we have been blessed to pursue with our distinguished collaborators,” said Dr. Goldknopf. “There will be some surprises for our colleagues at ICAD that we are particularly excited about because they have the potential to guide us towards improvements in treatment for this awful illness.” Dr. Goldknopf will present two of the posters at ICAD, one on NuroPro® AD biomarkers for Alzheimer’s specific diagnosis and the other on NuroPro® AD diagnostic clinical validation trials. Dr. Sabbagh will present a third poster on prospective clinical validation of the use of protein biomarkers from newly drawn patient sera for diagnosis of Alzheimer’s disease, and Dr. Bosquez will present a fourth poster on NuroPro® AD protein biomarkers and drug response.

“We are proud that Dr. Goldknopf will be joined this year by two members of our scientific advisory board, Dr. Sabbagh and Dr. Bosquez, in presenting to ICAD 2010,” said Helen R. Park, MS, Chief Executive Officer of Power3. “For us to present four posters at the same time at such a prestigious forum speaks to the depth of our science and our commitment to improving the outcomes for patients with Alzheimer’s disease. This work, in conjunction with the recent filing of our joint patent application with StemTroniX, bodes well for the upcoming acquisition of StemTroniX by PWRM.”

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.

Visit Power 3 Medical Products Inc. (PWRM.OB) for more information at www.Power3Medical.com

Popular Inc. (NasdaqGS: BPOP)

BPOP reported a net loss of $85.1 million for the quarter ended March 31, 2010, compared with a net loss of $213.2 million for the quarter ended December 31, 2009, and a net loss of $52.5 million for the quarter ended March 31, 2009.

Recently, BPOP announced that the Corporation has mailed to its stockholders a supplement to its Proxy Statement dated March 15, 2010. The supplement clarifies that broker non-votes and abstentions will not be counted as either a vote cast for or a vote cast against a nominee for director of the Corporation at the Annual Meeting of Stockholders to be held on May 4, 2010.

About Popular Inc.

Popular, Inc., through its subsidiaries, provides a range of retail and commercial banking products and services in Puerto Rico, the United States, Venezuela, the Dominican Republic, El Salvador, and Costa Rica. It also provides vehicle financing, leasing, and daily rental services; mortgage loans; and insurance agency and brokerage, and reinsurance services, as well as offers financial advisory, investment, and security brokerage services for institutional and retail customers.

Visit Popular Inc. (BPOP) for more information at http://www.popularinc.com

***************************ADVERTISEMENTS**************************

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and disseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.

PWRMpennyotcstock0430